Cerity Partners LLC Cuts Stock Position in Boston Scientific Corporation $BSX

Cerity Partners LLC lessened its holdings in Boston Scientific Corporation (NYSE:BSX) by 5.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,226,179 shares of the medical equipment provider’s stock after selling 75,325 shares during the period. Cerity Partners LLC’s holdings in Boston Scientific were worth $119,712,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of BSX. Steph & Co. bought a new stake in shares of Boston Scientific in the 3rd quarter worth about $25,000. Financial Consulate Inc. purchased a new position in Boston Scientific in the third quarter worth about $25,000. FWL Investment Management LLC bought a new stake in Boston Scientific during the second quarter worth approximately $26,000. Sound Income Strategies LLC raised its position in Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares during the period. Finally, Kilter Group LLC bought a new stake in shares of Boston Scientific in the 2nd quarter valued at approximately $30,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Up 2.3%

BSX stock opened at $97.70 on Wednesday. Boston Scientific Corporation has a 12 month low of $85.98 and a 12 month high of $109.50. The firm’s 50-day moving average is $97.72 and its 200 day moving average is $100.85. The company has a market capitalization of $144.84 billion, a PE ratio of 52.25, a P/E/G ratio of 1.69 and a beta of 0.67. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.04. The company had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The firm’s quarterly revenue was up 20.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analyst Upgrades and Downgrades

BSX has been the topic of several analyst reports. UBS Group reissued a “buy” rating on shares of Boston Scientific in a research report on Wednesday, December 17th. BTIG Research reissued a “buy” rating and issued a $132.00 target price on shares of Boston Scientific in a research note on Friday, November 21st. Barclays raised their target price on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a report on Thursday, October 2nd. Leerink Partners upped their price target on shares of Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, October 1st. Finally, Canaccord Genuity Group decreased their price objective on shares of Boston Scientific from $132.00 to $131.00 and set a “buy” rating for the company in a research note on Wednesday, December 17th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $124.95.

Insider Buying and Selling

In other news, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total value of $4,973,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $17,739,678.74. This represents a 21.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 93,095 shares of company stock valued at $9,305,450 over the last quarter. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.